The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll · Nature reviews. Cancer · 2012
Cited by 13,776 works. doi:10.1038/nrc3239 Open-access PDF
Authors
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4